This cohort study analyzed the relationship between different formulations of menopausal hormone therapy (HT) and breast cancer risk, finding that estrogen-only therapies (both bioidentical and animal-derived) did not significantly increase breast cancer risk, while synthetic progestins were more strongly associated with an increased risk. The study highlights a 12% increased
